Danaher (NYSE:DHR) Price Target Raised to $226.00

Danaher (NYSE:DHR - Get Free Report) had its price objective boosted by stock analysts at Robert W. Baird from $225.00 to $226.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has an "outperform" rating on the conglomerate's stock. Robert W. Baird's price objective indicates a potential upside of 18.96% from the company's current price.

A number of other brokerages also recently issued reports on DHR. Guggenheim reiterated a "buy" rating and issued a $250.00 price target on shares of Danaher in a report on Wednesday, April 23rd. Barclays restated an "overweight" rating and set a $225.00 target price (up from $215.00) on shares of Danaher in a report on Tuesday, June 24th. The Goldman Sachs Group dropped their target price on shares of Danaher from $260.00 to $240.00 and set a "neutral" rating for the company in a report on Wednesday, April 23rd. HSBC dropped their target price on shares of Danaher from $270.00 to $240.00 in a report on Friday, April 25th. Finally, Citigroup restated a "buy" rating on shares of Danaher in a report on Monday, April 7th. Three research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $248.48.

Danaher Stock Down 2.5%

Shares of DHR stock traded down $4.81 during trading on Friday, reaching $189.98. The company's stock had a trading volume of 4,239,169 shares, compared to its average volume of 3,523,488. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.43 and a quick ratio of 1.05. The company has a market capitalization of $135.96 billion, a price-to-earnings ratio of 36.89, a P/E/G ratio of 2.67 and a beta of 0.77. The stock's 50-day moving average price is $196.13 and its 200 day moving average price is $205.03. Danaher has a 1-year low of $171.00 and a 1-year high of $281.70.

Danaher (NYSE:DHR - Get Free Report) last posted its earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.26. Danaher had a return on equity of 10.80% and a net margin of 15.81%. The firm had revenue of $5.74 billion during the quarter, compared to analysts' expectations of $5.58 billion. On average, research analysts anticipate that Danaher will post 7.63 EPS for the current year.

Insider Buying and Selling at Danaher

In related news, EVP Christopher Paul Riley sold 15,805 shares of the company's stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total value of $3,129,390.00. Following the completion of the sale, the executive vice president owned 15,179 shares of the company's stock, valued at $3,005,442. This represents a 51.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Chairman Steven M. Rales sold 1,250,000 shares of the company's stock in a transaction dated Monday, May 12th. The shares were sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the completion of the sale, the chairman directly owned 3,105,808 shares of the company's stock, valued at $611,036,665.92. The trade was a 28.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 11.10% of the company's stock.

Institutional Trading of Danaher

Institutional investors and hedge funds have recently bought and sold shares of the stock. Fortis Capital Advisors LLC increased its position in Danaher by 1.3% in the fourth quarter. Fortis Capital Advisors LLC now owns 3,983 shares of the conglomerate's stock worth $914,000 after buying an additional 50 shares during the last quarter. Fayez Sarofim & Co increased its position in Danaher by 0.6% in the fourth quarter. Fayez Sarofim & Co now owns 8,287 shares of the conglomerate's stock worth $1,902,000 after buying an additional 50 shares during the last quarter. Coastal Bridge Advisors LLC increased its position in Danaher by 4.8% in the fourth quarter. Coastal Bridge Advisors LLC now owns 1,099 shares of the conglomerate's stock worth $252,000 after buying an additional 50 shares during the last quarter. Perennial Investment Advisors LLC grew its position in shares of Danaher by 2.2% in the fourth quarter. Perennial Investment Advisors LLC now owns 2,343 shares of the conglomerate's stock valued at $538,000 after purchasing an additional 51 shares in the last quarter. Finally, MGO One Seven LLC grew its position in shares of Danaher by 1.3% in the fourth quarter. MGO One Seven LLC now owns 4,285 shares of the conglomerate's stock valued at $984,000 after purchasing an additional 53 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company's stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.